SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community anticipates a potential breakout, with many pointing to technical indicators suggesting a move is imminent. Some users are speculating on potential partnerships and real-world asset (RWA) integration driving future growth. Community sentiment is largely bullish, with many calls for it to catch up with other coins.

Pump.fun

$PUMP.X is trending as the community discusses its potential within the meme coin space and the broader Solana ecosystem. Talk centers on its strong community and potential for significant market cap growth, with some drawing comparisons to other successful cryptocurrencies.  The platform's unique approach to token creation and streaming is also generating buzz.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending as the community discusses its potential, governance, and recent price action, while closely watching key support levels. A recent proposal to recall COMP tokens and the governance around it has sparked debate, with some fearing centralized control while others seek stability. Despite some frustration over its performance relative to other DeFi tokens, many holders express long-term bullish sentiment, citing its low supply and potential for growth as the broader crypto market improves.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending due to recent exchange listings and speculation about its potential to mirror the success of other decentralized exchanges. Community members are actively discussing its strong backing and comparing it to competitors like $HYPE.X, while also anticipating a potential surge towards a multi-billion market cap.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI.X is trending due to its recent rebrand and strong community, with many users expressing bullish sentiment. The community emphasizes that WAGMI is more than just a meme; it's a culture and a belief system. Discussions also highlight the project's longevity and commitment, further fueling positive momentum.

A tasty meme token that will brighten up your portfolio! Try a dash of heat and dive into a world of friendly community. NOMDOG is more than just a meme token. It’s a symbol of a united community of dog lovers, foodies, and crypto enthusiasts. We’re building a fun, open ecosystem where everyone can not only invest but also enjoy themselves by joining contests, quizzes, and charitable initiatives.

NOMDOG

NOMDOG.X is trending as community members highlight its potential for significant gains, urging others to buy in. Discussions center on positive price movement and strong technical setup. The coin's connection to SOL.X and BTC.X is also being mentioned.

WTF Opossum is a Meme token on solana Blockchain with utilities and tools for traders and token owners as well. Launched in July 2024. The project built a vote for exposure telegram bot with a leaderboard for tokens on multiple blockchains. The variety of tools contain the voting agent, contract scanner and market details checker. The $WTFO token itself was designed as a unique meme character. An opossum, the symbol of immortals. Just like opossums, WTFO is a surviver, focusing on it's utilities and the fun aspect of communities as being a real meme project.

WTF Opossum

WTF Opossum ($WTFO.X) is trending as the community highlights its meme power, utility, and burn mechanics as key differentiators. Community members are also discussing the token's longevity, continued development, and strong ecosystem on Solana. The conversation suggests a growing sentiment that $WTFO is more than just a meme coin, but a project with long-term potential.

Terner is an AI-powered platform on Solana that enables users to create, deploy, and crowdfund innovative projects through natural language interaction. The platform combines advanced AI capabilities with blockchain technology to democratize project creation, offering tools for building web applications, bots, and various digital solutions while providing automated deployment and investment opportunities for creators and investors alike.

Terner

Terner.X is trending as the community discusses its potential as an AI-powered project creation platform on the Solana blockchain, with some aiming for a significant market cap increase. Conversations revolve around ease of purchase via Phantom Wallet, the utility of the platform, and the promise of long-term gains. However, some users are cautioning against potential rug pulls.

TOSHI

TOSHI.X is trending due to recent listings on South Korean exchanges and Binance futures, sparking excitement about increased accessibility and trading volume. The community is focused on breaking resistance levels and anticipating further gains, with some members expressing confidence in the project's long-term potential. Many believe that with more exchange listings and community support, TOSHI.X has the potential to reach new all-time highs.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in February 2019 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics ($GPCR) is trending as traders discuss risk-adjusted buyout scenarios and upcoming catalysts like FDA orphan drug designation and H2 2025 pipeline readouts. The community is also watching short interest, call option flow, and potential squeeze setups. Some analysts are drawing comparisons to competitors like $LLY and $VKTX in the obesity and oral peptide space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for August 22nd

INKT, MNR and CSIQ have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2025.

MiNK Therapeutics stock falls after William Blair downgrade

Investing.com -- MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downgraded the shares following the spectacular rally.

Shares of MiNK Therapeutics, Inc. (INKT) skyrocketed on Friday following the publication of a case from its clinical trial describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer following treatment with its cell therapy.<a href="https://stocktwits.com/symbol/INKT">INKT shares</a> were up about 466% at the time of writing.The patient had progressed after multiple lines of therapy, including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors.However, they had complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later, after receiving a single infusion of agenT-797 alongside the cancer drug nivolumab.AgenT-797 is an off-the-shelf, cryopreserved invariant natural killer T (iNKT) cell therapy. It utilizes iNKT cells, which contribute to anti-tumor effects, from a healthy donor to treat a recipient.Donor iNKT cells were detectable up to six months post-infusion in the patient, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-announces-publication-complete-remission">said</a>.AgenT-797 is currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. The company said that its ongoing mid-stage trial in gastric cancer is actively enrolling, with data readouts expected in the coming months.On Stocktwits, retail sentiment around INKT jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_9_59_40_AM_png_9597d54c42.webp" alt="INKT's Sentiment Meter and Message Volume as of 10 a.m. ET on July 11, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>INKT's Sentiment Meter and Message Volume as of 10 a.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company would have a share offering in the evening as it “absolutely” needs more money.<stembedurl>https://stocktwits.com/pow7904/message/620632189</stembedurl>MiNK ended the first quarter with a cash balance of $3.2 million.INKT stock is up by about 519% this year and by about 345% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/levi-stock-surges-after-analysts-raise-price-target-on-stock-retail-sentiment-extremely-bullish/ch8cXLQR5ZF">Levi Stock Surges After Analysts Raise Price Target On Stock, Retail Sentiment ‘Extremely Bullish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy

“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said.

Equity

Why MiNK Therapeutics Stock Is Up 11% Monday

MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.
read more...

HC Wainwright Lowers MiNK Therapeutics (NASDAQ:INKT) Price Target to $9.00

MiNK Therapeutics (NASDAQ:INKT  Free Report) had its target price reduced by HC Wainwright from $10.00 to $9.00 in a report released on Thursday morning, Benzinga reports. They currently have...

Q4 2023 Mink Therapeutics Inc Earnings Call Transcript

MiNK Reports Fourth Quarter and Year-End 2023 Results

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development...

Earnings Outlook For MiNK Therapeutics

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...

MiNK Therapeutics announces preclinical data from MiNK-215

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

MiNK Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.86	--	--	N/A
Q2 '25	-$0.55	-$1.06	-93.90%	MISSED
Q1 '25	-$0.61	-$0.70	-15.19%	MISSED
Q4 '24	-$0.48	-$0.62	-29.17%	MISSED
Q3 '24	-$0.08	-$0.50	-524.48%	MISSED

INKT
MiNK Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest INKT News

INKT MiNK Therapeutics Inc